What is Dash Bio?
Dash Bio operates at the intersection of advanced robotics, artificial intelligence, and life sciences. The company provides a fully automated, GLP-compliant lab platform designed to accelerate clinical development cycles. By replacing manual, error-prone processes with high-precision automated workflows, Dash Bio enables biopharma teams to achieve faster results and superior data integrity. This technological edge is essential for organizations aiming to reduce the time-to-market for complex therapeutic candidates, positioning Dash Bio as a critical infrastructure provider in the global drug development ecosystem.
How much funding has Dash Bio raised?
Dash Bio has raised a total of $47.5M across 3 funding rounds:
Angel/Seed
$6.5M
Unspecified
$11M
Private Equity
$30M
Angel/Seed (2024): $6.5M with participation from Swift Ventures, Freestyle, and LifeX Labs
Unspecified (2025): $11M led by Swift Ventures, Freestyle Capital, LifeX Ventures, and Cybernetix Ventures
Private Equity (2026): $30M, investors not publicly disclosed
Key Investors in Dash Bio
Swift Ventures
Swift Ventures is an early-stage venture capital firm that focuses on backing founders with company-building expertise, specifically targeting true AI companies through their AI Index initiative.
Freestyle Capital
Freestyle VC is an early-stage venture capital firm recognized for investing in numerous technology companies, focusing on supporting startups during their initial funding rounds with strategic guidance.
LifeX Ventures
Life Extension Ventures focuses on extending life and improving health through innovative scientific breakthroughs, partnering with startups in the fields of AI, healthtech, and climate technology.
What's next for Dash Bio?
With the recent infusion of capital, Dash Bio is well-positioned to transition into a phase of rapid enterprise-level scaling. The strategic roadmap likely includes the expansion of its automated laboratory capacity and the further refinement of its AI-driven data analytics capabilities. By deepening its integration within the biopharma R&D pipeline, the company aims to solidify its market position as the standard for high-speed, high-quality bioanalysis. Future growth will likely focus on increasing throughput to meet the rising demand for accelerated clinical trials, ensuring that the firm remains at the forefront of the digital transformation in healthcare.
See full Dash Bio company page
